Upstate Active Clinical Trials

Study Title:

2215-CL-0302: A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of FLT3 Inhibitor Gileritinib (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Remission

Upstate Institutional Review Board (IRB) Number:

976763

Study/Protocol ID:

2215-CL-302

Study Phase:

Phase 3

Patient Age Group:

Adults

Principal Investigator:

Teresa C Gentile, MD, PhD

What is involved if I participate?

  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    No

Where will the study take place?

Upstate Medical University

ClinicalTrials.Gov ID:

NCT02927262

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Erinn Mcdowell, MS, CCRP
Phone: 315-464-8230
Email: mcdowele@upstate.edu

Return to Previous Page || Search Again